Lifeward announces U.S. insurance company approved payment for ReWalk 7

Lifeward (LFWD) announced that a major U.S. health insurance company has approved the payment for a ReWalk 7 Personal Exoskeleton for one of its beneficiaries. This decision by one of the largest commercial health insurers in the U.S. marks the first approval for payment of the all-new ReWalk 7 Personal Exoskeleton for individuals with spinal cord injury, which was launched for U.S. sales on April 15, 2025. “Expanding access for individuals with SCI to our ReWalk Personal Exoskeleton has been a key strategic initiative for Lifeward,” said Larry Jasinski, CEO of Lifeward. “Commercial health insurers cover a significant proportion of individuals with SCI in the U.S. The decision to cover this device demonstrates the momentum of our efforts to engage with more commercial health insurers and solidify a growth trajectory for the Company.”